PMID- 34788123
OWN - NLM
STAT- MEDLINE
DCOM- 20220421
LR  - 20220531
IS  - 2687-8941 (Electronic)
IS  - 2687-8941 (Linking)
VI  - 7
DP  - 2021 Sep
TI  - Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase-Positive 
      Non-Small-Cell Lung Cancer in the Middle East and North Africa.
PG  - 1556-1563
LID - 10.1200/GO.21.00067 [doi]
LID - GO.21.00067
AB  - PURPOSE: Anaplastic lymphoma kinase (ALK) gene alterations are potent oncogenic 
      drivers in non-small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors 
      targeting the ALK pathway are effective in treating ALK-positive NSCLC. Around 5% 
      of Asian and White patients with NSCLC have ALK-positive tumors, but ALK 
      rearrangement prevalence data in the Middle East and North Africa (MENA) region 
      are limited. METHODS: In this noninterventional epidemiology study, 
      histologically confirmed nonsquamous NSCLC samples retained for < 5 years in 
      tissue banks at six centers in MENA were retrospectively analyzed for ALK 
      rearrangement using the VENTANA immunohistochemistry (IHC) method. Patient 
      characteristics obtained were analyzed for association with ALK rearrangement. 
      Concordance between IHC and Vysis fluorescence in situ hybridization (FISH) ALK 
      detection methods was assessed in a subset of samples. RESULTS: Four hundred 
      forty-eight tissue samples were analyzed using IHC: 137 (30.6%) in Lebanon, 104 
      (23.2%) in Saudi Arabia, 97 (21.7%) in Egypt, 80 (17.9%) in the United Arab 
      Emirates, and 30 (6.7%) in Morocco. On the basis of IHC, the prevalence was 8.7% 
      (95% CI, 6.3 to 11.7) for ALK-positivity and 91.3% (95% CI, 88.3 to 93.7) for 
      ALK-negativity. On the basis of FISH (n = 148), the prevalence was 5.4% 
      positivity and 81.8% negativity (12.8% nonevaluable). Concordance between IHC and 
      FISH (n = 129) was 98.4% (95% CI, 94.2 to 99.8) for negative agreement and 98.5% 
      (95% CI, 94.5 to 99.8) for overall agreement. Univariate analysis showed that ALK 
      rearrangement was significantly associated with epidermal growth factor receptor 
      wild-type status (P = .03) but was not significantly associated with sex, race, 
      smoking history, or histologic subtype. CONCLUSION: Our findings suggest that ALK 
      rearrangements are more prevalent in MENA than other geographic regions. High 
      concordance was found between FISH and IHC. Except for epidermal growth factor 
      receptor wild-type status, no clinicopathologic characteristics were associated 
      with ALK-positive NSCLC.
FAU - Jazieh, Abdul Rahman
AU  - Jazieh AR
AUID- ORCID: 0000-0001-5465-7698
AD  - King Saud bin Abdulaziz University for Health Sciences, King Abdullah 
      International Medical Research Center, Ministry of National Guard Hospital, 
      Riyadh, Saudi Arabia.
FAU - Gaafar, Rabab
AU  - Gaafar R
AD  - National Cancer Institute, Cairo University, Cairo, Egypt.
FAU - Errihani, Hassan
AU  - Errihani H
AD  - National Institute of Oncology, Mohammed V University, Rabat, Morocco.
FAU - Jaafar, Hassan
AU  - Jaafar H
AD  - Sheikh Khalifa Specialty Hospital, Ras Al Khaimah, United Arab Emirates.
FAU - Al Dayel, Fouad
AU  - Al Dayel F
AD  - King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
FAU - Bahnassy, Abeer A
AU  - Bahnassy AA
AD  - National Cancer Institute, Cairo University, Cairo, Egypt.
FAU - El Kadi, Hatem
AU  - El Kadi H
AD  - Pfizer Inc, Africa and Middle East.
FAU - Abdallah, Mohamed Magdy
AU  - Abdallah MM
AUID- ORCID: 0000-0001-8031-6061
AD  - Pfizer Inc, Egypt.
FAU - Zaatari, Ghazi
AU  - Zaatari G
AD  - American University of Beirut Medical Center, Beirut, Lebanon.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - JCO Glob Oncol
JT  - JCO global oncology
JID - 101760170
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Anaplastic Lymphoma Kinase/genetics/*metabolism
MH  - *Carcinoma, Non-Small-Cell Lung/epidemiology/genetics/metabolism
MH  - ErbB Receptors/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lebanon/epidemiology
MH  - *Lung Neoplasms/epidemiology/genetics/metabolism
MH  - Prevalence
MH  - Receptor Protein-Tyrosine Kinases/genetics/metabolism
MH  - Retrospective Studies
PMC - PMC8613346
COIS- Abdul Rahman JaziehStock and Other Ownership Interests: Innovative Healthcare 
      InstituteResearch Funding: MSD Oncology, AstraZeneca, PfizerTravel, 
      Accommodations, Expenses: Bristol Myers SquibbOther Relationship: MSD (Inst) 
      Rabab GaafarConsulting or Advisory Role: Pfizer, AstraZeneca, MSD 
      OncologyResearch Funding: Roche Hassan ErrihaniConsulting or Advisory Role: 
      Pfizer, Roche, MSD, Merck, Janssen Oncology, AstraZenecaSpeakers' Bureau: 
      Novartis, Amgen, Astellas Pharma, ServierResearch Funding: RocheTravel, 
      Accommodations, Expenses: Pierre Fabre (Inst), Merck (Inst) Hatem El 
      KadiEmployment: Pfizer Mohamed Magdy AbdallahEmployment: PfizerStock and Other 
      Ownership Interests: PfizerResearch Funding: PfizerTravel, Accommodations, 
      Expenses: PfizerNo other potential conflicts of interest were reported.
EDAT- 2021/11/18 06:00
MHDA- 2022/04/22 06:00
PMCR- 2021/11/17
CRDT- 2021/11/17 17:14
PHST- 2021/11/17 17:14 [entrez]
PHST- 2021/11/18 06:00 [pubmed]
PHST- 2022/04/22 06:00 [medline]
PHST- 2021/11/17 00:00 [pmc-release]
AID - GO.21.00067 [pii]
AID - 10.1200/GO.21.00067 [doi]
PST - ppublish
SO  - JCO Glob Oncol. 2021 Sep;7:1556-1563. doi: 10.1200/GO.21.00067.